These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23436263)

  • 21. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters.
    Ward KW; Coon DJ; Magiera D; Bhadresa S; Nisbett E; Lawrence MS
    Drug Metab Dispos; 2008 Apr; 36(4):715-20. PubMed ID: 18227143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.
    Naritomi Y; Terashita S; Kimura S; Suzuki A; Kagayama A; Sugiyama Y
    Drug Metab Dispos; 2001 Oct; 29(10):1316-24. PubMed ID: 11560875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.
    Yamazaki S; Toth LN; Black ML; Duncan JN
    Drug Metab Dispos; 2004 Apr; 32(4):398-404. PubMed ID: 15039292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
    Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
    Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans.
    Nagilla R; Ward KW
    J Pharm Sci; 2004 Oct; 93(10):2522-34. PubMed ID: 15349961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
    Obach RS
    Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of neural networks for the prediction of human pharmacokinetic parameters.
    Ritschel WA; Akileswaran R; Hussain AS
    Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):629-43. PubMed ID: 8786678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
    Sayama H; Komura H; Kogayu M
    Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of intrinsic clearance for prediction of human hepatic clearance.
    Chao P; Uss AS; Cheng KC
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):189-98. PubMed ID: 20073997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited.
    Wang W; Prueksaritanont T
    Biopharm Drug Dispos; 2010 May; 31(4):253-63. PubMed ID: 20437464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance.
    Nagilla R; Frank KA; Jolivette LJ; Ward KW
    J Pharmacol Toxicol Methods; 2006; 53(2):106-16. PubMed ID: 16188462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interspecies allometric scaling. Part I: prediction of clearance in large animals.
    Mahmood I; Martinez M; Hunter RP
    J Vet Pharmacol Ther; 2006 Oct; 29(5):415-23. PubMed ID: 16958787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
    Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
    Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk.
    Timchalk C
    Toxicology; 2004 Jul; 200(1):1-19. PubMed ID: 15158559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.